Advertisement
Advertisement
U.S. markets open in 3 hours 14 minutes
Advertisement
Advertisement
Advertisement
Advertisement

PharmaCyte Biotech, Inc. (PMCB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1800+0.0900 (+4.31%)
At close: 04:00PM EDT
2.1700 -0.01 (-0.46%)
After hours: 04:17PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close2.0900
Open2.1100
Bid0.0000 x 1100
Ask0.0000 x 800
Day's Range2.1001 - 2.1872
52 Week Range1.7900 - 22.1650
Volume142,163
Avg. Volume463,345
Market Cap45.172M
Beta (5Y Monthly)-0.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PMCB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PharmaCyte Biotech, Inc.
    HALO: Raising target price to $60.00HALOZYME THERAPEUTICS INC has an Investment Rating of BUY; a target price of $60.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • PR Newswire

    IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

    Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 6.1% of the outstanding common stock of the Company, today announced that it has nominated a slate of seven (7) highly qualified director candidates for election to the PharmaCyte Board of Directors at the Company's upcoming 2022 annual meeting of stockholders. Iroquois als

  • Business Wire

    PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

    LAS VEGAS, June 15, 2022--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following statement in response to the second letter issued by Iroquois Capital (Iroquois) on June 9, 2022:

  • Business Wire

    PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

    LAS VEGAS, June 13, 2022--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will represent PharmaCyte at the 2022 BIO International Convention (BIO) being held at the San Diego Convention Center in San Diego, California, June 13-16.

Advertisement
Advertisement